Stockscreener 앱 받기
13.55
0.37%
0.05
시간 외 거래:
13.55
전일 마감가:
$13.50
열려 있는:
$13.51
하루 거래량:
1.43M
Relative Volume:
0.18
시가총액:
$3.56B
수익:
$6.16B
순이익/손실:
$246.00M
주가수익비율:
14.43
EPS:
0.9387
순현금흐름:
$708.00M
1주 성능:
+1.12%
1개월 성능:
+1.57%
6개월 성능:
+90.58%
1년 성능:
+37.42%
1일 변동 폭
$13.49
$13.55
1주일 범위
$13.39
$13.55
52주 변동 폭
$5.69
$13.55
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.55 | 3.55B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,229.93 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.31 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.38 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.59 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon & Co. Actuals & Estimates (NYSE:OGN) - TradingView
Organon & Co updates strategic focus, shares watched on NYSE - AD HOC NEWS
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP - TradingView
Price to earnings forward of Organon & Co. – NYSE:OGN - TradingView
Price to earnings forward of Organon & Co. – LSE:0A9W - TradingView
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada - MSN
Mayne Pharma appoints former Organon & Co executive Meghan Rivera to board - MSN
(OGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of Organon & Co. – NYSE:OGN - TradingView
Enterprise value to EBITDA forward of Organon & Co. – LSE:0A9W - TradingView
Enterprise value to revenue forward of Organon & Co. – NYSE:OGN - TradingView
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Organon & Co. (OGN) InvestorsLead Plaintiff Deadline on July 22, 2025 - The National Law Review
Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Enterprise value to EBIT forward of Organon & Co. – LSE:0A9W - TradingView
Organon & Co updates earnings timing, shares watched by health care investors - Ad-hoc-news.de
Organon celebrates 5 years of expanding healthcare access - Manila Standard
Organon & Co (OGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organon & Co stock hits 52-week high at $13.49 - Investing.com UK
Organon & Co stock hits 52-week high at $13.49 By Investing.com - Investing.com Australia
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? - TradingView
OGN Forecast — Price Target — Prediction for 2027 - TradingView
Gorvins supports Organon Trustees through acquisition process - Marketing Stockport
Organon & Co (OGN) Institutional Confidence - TradingKey
Samsung Bioepis and Organon Expand Canadian Biosimilars Alliance with PYZCHIVA® Commercialisation Agreement - BioPharma APAC
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co.OGN - Business Wire
Organon launches BILDYOS and TUZEMTY Denosumab biosimilars in Canada - grafa.com
Henlius And Organon Deepen Canada’s Denosumab Biosimilar Race - Citeline News & Insights
Organon puts two Prolia, Xgeva biosimilars on sale in Canada - Stock Titan
Organon completes licensing deal for hormone-free IUD Miudella - Investing.com UK
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG) - GlobeNewswire Inc.
Organon secures global licensing deal for MIUDELLA copper IUD - grafa.com
Organon & Co. (OGN) is attracting investor attention: Here is what you should know - MSN
Organon To Commercialize Samsung Bioepis’ Stelara Biosimilar In Canada - insights.citeline.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Organon completes licensing deal for hormone-free IUD Miudella By Investing.com - Investing.com Australia
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device - Business Wire
Lombard Odier Asset Management (USA) Corp's Organon & Co(OGN) Holding History - GuruFocus
Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada - koreabiomed.com
OGNOrganon & Co Stock Price and Quote - Finviz
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA - Business Wire
Organon and Samsung Bioepis expand Canadian biosimilar deal - grafa.com
Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in Canada - Businesskorea
Organon gains rights to Samsung biosimilar in Canada By Investing.com - Investing.com Nigeria
Organon gains rights to Samsung biosimilar in Canada - Investing.com
Organon & Co (OGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FDA expands Organon’s tocilizumab biosimilar indications By Investing.com - Investing.com Nigeria
Organon & Co (OGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
1.21%
자본화:
|
볼륨(24시간):